Two just-published royalty rate references are offering updated data on licensing deal terms for pharma and biotech as well as medical device and diagnostic technologies.
The newly expanded 9th Edition of Royalty Rates for Pharmaceuticals & Biotechnology includes a 30% increase in the number of reported license agreements over the previous edition. It contains over 550 transactions that include the technology licensed, royalty rates, upfront license fees, and milestone payments.
A wide variety of technologies are represented, including in categories such as Alzheimer’s, asthma, cardiovascular, cancer, contraception, diabetes, dermatology, drug delivery, hepatitis, pain management, personal care, sleep therapy, and vaccines. For complete details, click here.
Also just released is the latest update to Royalty Rates for Medical Devices & Diagnostics, with 25% more deals than the previous edition, new tables and charts, new data from jury awards, and expert guidance covering royalty audits. If your interest is focused primarily on the medical device industry or you’re evaluating a deal in that sector, you can access this valuable data at a fraction of the cost of larger data sets and databases. For complete details, click here.
